Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing

Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing

KRAS mutation status is established as a predictive biomarker of benefit from anti-EGFr therapies. Mutations are normally assessed using DNA extracted from one formalin-fixed, paraffin-embedded (FFPE) tumor block. We assessed heterogeneity of KRAS and BRAF mutation status intra-tumorally (multiple b...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Susan D. Richman, Philip Chambers, Matthew T. Seymour, Catherine Daly, Sophie Grant, Gemma Hemmings, Philip Quirke
Định dạng: Bài viết
Ngôn ngữ:English
Được phát hành: Hindawi Limited 2011-01-01
Loạt:Analytical Cellular Pathology
Truy cập trực tuyến:http://dx.doi.org/10.3233/ACP-2011-0005

Internet

http://dx.doi.org/10.3233/ACP-2011-0005

Những quyển sách tương tự